Peter C. Albertsen, MD
PSA controversy has practical implications
The authors of a recent study should be commended for exploring a large national database in an attempt to understand contemporary prostate cancer screening and treatment practices.
Diabetes, prostate cancer link: Surprising, or not?
Men with abnormal findings on digital rectal exam or other indicators of prostate cancer should be tested, but the evidence is insufficient to justify preferentially screening diabetic men because they may be at a higher risk of developing clinically significant prostate cancer.
Robotic vs. open radical prostatectomy: Who pays the cost?
Higher costs without greater benefits means that robotic procedures are at risk of not being supported by efforts to control health care costs.
Consumer-driven health care may take a new twist for urologists
During the next few years, insurers will begin demanding evidence that different products and services, such as the robot, truly provide added value in terms of better outcomes and shorter hospital stays.
How to interpret Gleason score in contemporary biopsy
Urologists counseling men with newly diagnosed prostate cancer often assess the risk posed by the disease in order to recommend an appropriate treatment strategy. During the past decade, clinicians have recognized that men with elevated PSA levels have a significant chance of harboring extracapsular disease. Another indicator of potentially advanced disease is the number of biopsy cores that are positive for disease and the percentage of each core that contains disease.